John Kirkwood, MD

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups

Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML

Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC

Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo